Agenus Liabilities 2024

Agenus Aktienanalyse

What does Agenus do?

Agenus Inc is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus started as a small start-up company focusing on the research of antibodies against chronic viral diseases. In 2000, the company developed the first approved therapeutic vaccine against cervical cancer in collaboration with GlaxoSmithKline. Since then, Agenus has expanded its business to the discovery, development, and commercialization of novel antibody and immunotherapies. The company has brought many groundbreaking medications to the market, including a cancer immunotherapy called Prophage, which is approved for the treatment of glioblastoma, an aggressive brain tumor. Agenus' business model focuses on the development of immunotherapies that utilize the body's immune system to fight against cancer or other diseases. The company's research and development programs are divided into three areas: antibody development, immunotherapy, and preclinical developments. Agenus has a comprehensive library of antibodies and utilizes them to develop new and innovative antibodies and antibody conjugates that can be used to treat cancer and autoimmune diseases. The company has also developed a range of immunotherapies aimed at supporting the body's immune system in fighting against cancer and other diseases, including therapies targeting checkpoint inhibitors that enhance the body's immune response to cancer cells. In addition, Agenus has a broad portfolio of preclinical programs aimed at developing new drugs and therapies for the treatment of cancer and other diseases. Agenus has introduced a range of products to the market that can be used for the treatment of cancer and other diseases, including Prophage, a personalized cancer vaccine tailored to each patient for the treatment of glioblastoma. Other products include Zalifrelimab, a checkpoint inhibitor that aims to enhance the body's immune response to cancer, INCAGN2385, another checkpoint inhibitor that enhances T-cell activity in the body, and INCAGN1949, an antibody therapy targeting the GITR protein that can help enhance the immune response against cancer cells. In summary, Agenus is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company has a long history in antibody research and development and has expanded its efforts to develop immunotherapies. Agenus has a comprehensive library of antibodies and has introduced a range of products to the market for the treatment of cancer and other diseases. With a broad portfolio of products and preclinical programs, Agenus remains a key player in the field of immunotherapies and is expected to drive further groundbreaking developments in the future. Agenus ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Agenus's Liabilities

Agenus's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Agenus's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Agenus's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Agenus's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Agenus’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Agenus stock

What is the level of liabilities of Agenus this year?

Agenus has a debt balance of 474.24 M USD this year.

What were the liabilities of Agenus compared to the previous year?

The liabilities of Agenus have increased by -0.12% dropped compared to the previous year.

What are the consequences of high debt for investors of Agenus?

High liabilities can pose a risk for investors of Agenus, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Agenus?

Low liabilities mean that Agenus has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Agenus affect the company?

An increase in liabilities of Agenus can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Agenus affect the company?

A decrease in the liabilities of Agenus can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Agenus?

Some factors that can influence the liabilities of Agenus include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Agenus so important for investors?

The liabilities of Agenus are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Agenus take to modify the liabilities?

To change its liabilities, Agenus can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Agenus pay?

Over the past 12 months, Agenus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agenus is expected to pay a dividend of 0 USD.

What is the dividend yield of Agenus?

The current dividend yield of Agenus is .

When does Agenus pay dividends?

Agenus pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Agenus?

Agenus paid dividends every year for the past 0 years.

What is the dividend of Agenus?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Agenus located?

Agenus is assigned to the 'Health' sector.

Wann musste ich die Aktien von Agenus kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Agenus from 11/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/22/2024.

When did Agenus pay the last dividend?

The last dividend was paid out on 11/22/2024.

What was the dividend of Agenus in the year 2023?

In the year 2023, Agenus distributed 0 USD as dividends.

In which currency does Agenus pay out the dividend?

The dividends of Agenus are distributed in USD.